212 related articles for article (PubMed ID: 26880104)
1. Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study.
Hansen MB; Rasmussen LS; Garred P; Bidstrup D; Madsen MB; Hyldegaard O
Crit Care; 2016 Feb; 20():40. PubMed ID: 26880104
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of Necrotising Soft Tissue Infections Aspects of the Innate Immune Response.
Hansen MB
Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673381
[TBL] [Abstract][Full Text] [Related]
3. Pentraxin 3, a Predicator for 28-Day Mortality in Patients With Septic Shock.
Jie H; Li Y; Pu X; Ye J
Am J Med Sci; 2017 Mar; 353(3):242-246. PubMed ID: 28262210
[TBL] [Abstract][Full Text] [Related]
4. Associations of Plasma Nitrite, L-Arginine and Asymmetric Dimethylarginine With Morbidity and Mortality in Patients With Necrotizing Soft Tissue Infections.
Hansen MB; Rasmussen LS; Garred P; Pilely K; Wahl AM; Perner A; Madsen MB; Hedegaard ER; Simonsen U; Hyldegaard O
Shock; 2018 Jun; 49(6):667-674. PubMed ID: 28863028
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of plasma pentraxin 3 levels in patients with septic shock admitted to intensive care.
Perez-San Martin S; Suberviola B; Garcia-Unzueta MT; Lavin BA; Campos S; Santibañez M
PLoS One; 2020; 15(12):e0243849. PubMed ID: 33301518
[TBL] [Abstract][Full Text] [Related]
6. Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study.
Hansen MB; Rasmussen LS; Svensson M; Chakrakodi B; Bruun T; Madsen MB; Perner A; Garred P; Hyldegaard O; Norrby-Teglund A;
Sci Rep; 2017 Feb; 7():42179. PubMed ID: 28176831
[TBL] [Abstract][Full Text] [Related]
7. SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study.
Polzik P; Grøndal O; Tavenier J; Madsen MB; Andersen O; Hedetoft M; Hyldegaard O
Sci Rep; 2019 Mar; 9(1):5098. PubMed ID: 30911053
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation-the protocol of the prospective cohort BIONEC study.
Hansen MB; Simonsen U; Garred P; Hyldegaard O
BMJ Open; 2015 May; 5(5):e006995. PubMed ID: 25967993
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions.
Song J; Park DW; Moon S; Cho HJ; Park JH; Seok H; Choi WS
BMC Infect Dis; 2019 Nov; 19(1):968. PubMed ID: 31718563
[TBL] [Abstract][Full Text] [Related]
10. Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections-A Prospective Observational Study.
Kristensen MK; Hansen MB; Madsen MB; Hansen CB; Pilely K; Hyldegaard O; Garred P
Front Immunol; 2020; 11():17. PubMed ID: 32082310
[No Abstract] [Full Text] [Related]
11. Prognostic factors in necrotizing soft-tissue infections (NSTI): A cohort study.
Hua C; Sbidian E; Hemery F; Decousser JW; Bosc R; Amathieu R; Rahmouni A; Wolkenstein P; Valeyrie-Allanore L; Brun-Buisson C; de Prost N; Chosidow O
J Am Acad Dermatol; 2015 Dec; 73(6):1006-12.e8. PubMed ID: 26412163
[TBL] [Abstract][Full Text] [Related]
12. Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection.
Hedetoft M; Hansen MB; Madsen MB; Johansen JS; Hyldegaard O
BMC Infect Dis; 2021 Oct; 21(1):1046. PubMed ID: 34627195
[TBL] [Abstract][Full Text] [Related]
13. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial.
Caironi P; Masson S; Mauri T; Bottazzi B; Leone R; Magnoli M; Barlera S; Mamprin F; Fedele A; Mantovani A; Tognoni G; Pesenti A; Gattinoni L; Latini R;
Eur J Clin Invest; 2017 Jan; 47(1):73-83. PubMed ID: 27864924
[TBL] [Abstract][Full Text] [Related]
14. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome.
Bastrup-Birk S; Skjoedt MO; Munthe-Fog L; Strom JJ; Ma YJ; Garred P
PLoS One; 2013; 8(9):e73119. PubMed ID: 24039869
[TBL] [Abstract][Full Text] [Related]
15. Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy.
Kim SB; Lee KH; Lee JU; Ann HW; Ahn JY; Jeon YD; Kim JH; Ku NS; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Mar; 58(2):370-379. PubMed ID: 28120568
[TBL] [Abstract][Full Text] [Related]
16. Predictors of mortality, limb loss, and discharge disposition at admission among patients with necrotizing skin and soft tissue infections.
Horn DL; Shen J; Roberts E; Wang TN; Li KS; O'Keefe GE; Cuschieri J; Bulger EM; Robinson BRH
J Trauma Acute Care Surg; 2020 Jul; 89(1):186-191. PubMed ID: 32102045
[TBL] [Abstract][Full Text] [Related]
17. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.
Mauri T; Bellani G; Patroniti N; Coppadoro A; Peri G; Cuccovillo I; Cugno M; Iapichino G; Gattinoni L; Pesenti A; Mantovani A
Intensive Care Med; 2010 Apr; 36(4):621-9. PubMed ID: 20119647
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients.
Muller B; Peri G; Doni A; Torri V; Landmann R; Bottazzi B; Mantovani A
Crit Care Med; 2001 Jul; 29(7):1404-7. PubMed ID: 11445697
[TBL] [Abstract][Full Text] [Related]
19. Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology.
Luo Q; He X; Ning P; Zheng Y; Yang D; Xu Y; Shang Y; Gao Z
Proteomics Clin Appl; 2019 Jul; 13(4):e1800117. PubMed ID: 30557448
[TBL] [Abstract][Full Text] [Related]
20. Source of Circulating Pentraxin 3 in Septic Shock Patients.
Albert Vega C; Mommert M; Boccard M; Rimmelé T; Venet F; Pachot A; Leray V; Monneret G; Delwarde B; Brengel-Pesce K; Mallet F; Trouillet-Assant S
Front Immunol; 2018; 9():3048. PubMed ID: 30687307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
